ADXS11-001

DRUG5 trials

Conditions

1)cervical cancer 2) A malignant tumor of the cervix the lowermost part of the uterusAdvanced Cervical CancerCancerCarcinoma, Non-Small-Cell LungCervical CancerHPV-16 +ve Oropharyngeal CarcinomaHead and Neck CancerHigh Risk Cervical Cancer

Phase 1

Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer

TerminatedNCT01598792

University of LiverpoolHPV-16 +ve Oropharyngeal Carcinoma

Start: 2012-02-29End: 2014-11-30Updated: 2016-05-18

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

TerminatedNCT02291055

Advaxis, Inc.Cancer, Cervical Cancer, Head and Neck Cancer

Start: 2015-04-30End: 2020-11-20Updated: 2023-03-20

Phase 2

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

WithdrawnNCT02531854

Advaxis, Inc.Carcinoma, Non-Small-Cell Lung

Start: 2018-12-31End: 2019-03-31Updated: 2023-12-19

Phase 3

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

TerminatedNCT02853604

Advaxis, Inc.Advanced Cervical Cancer, High Risk Cervical Cancer

Start: 2015-12-15End: 2019-07-31Updated: 2023-03-14

Phase 3 study of ADXS11-001 administered following chemoradiation as adjuvant treatment for high risk locally advanced cervical cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)

NL-OMON47237

Advaxis, Inc1)cervical cancer 2) A malignant tumor of the cervix the lowermost part of the uterus

Target: 6Updated: 2024-02-28

Related Papers

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.

2021-09-2765 citations

Advances in Cervical Cancer